Glaukos reports Q2 EPS (55c), consensus (55c)

Reports Q2 revenue $80.4M, consensus $74.7M. “Our record second quarter results highlighted by double-digit topline growth reflect the successful execution of our commercial strategies thus far in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to prudently invest in and advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”